Dystrophic Epidermolysis Bullosa Treatment

About the Disease

Dystrophic Epidermolysis Bullosa (DEB) is a rare genetic disorder characterized by fragile and blistering skin. DEB is caused by mutations in the COL7A1 gene that affects the skin and mucosal tissues. Patients with DEB commonly suffer from open wounds, which can lead to skin infections and fibrosis, which can cause the fusion of fingers and toes. Ultimately, these patients are also at an increased risk of developing an aggressive form of squamous cell carcinoma, which, in severe cases, can be fatal.

About our Patient Care

Our dedicated Care Team works with the physician's office and insurance on a patient's behalf to give our patients more time to focus on their treatment and quality of life. We are here to listen, provide counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance.

As part of treatment, we provide:

Dedicated Care Team

We provide prescribers and patients with a dedicated care team for each of our disease-state programs. This includes a primary pharmacy contact, clinical education, side-effects management, scheduled refill calls, and a direct phone, fax, and email address.

Shipping and Coordination of Care

We provide free overnight delivery of medications and necessary medical supplies and manage care coordination between prescribers, sites of care, nurses, and patients to ensure dispense and drug delivery aligns with the date and location of service.

Financial Assistance

We successfully identify and assist in enrolling patients into all manufacturer co-pay and foundation support programs to minimize a potential financial burden to patients.